Aditxt's Subsidiary Pearsanta Receives an Invitation to Submit Full Proposal for the U.S. Department of Defense Pilot Award for the Development of its Mitomic® Ovarian Test

Stock Information for Appili Therapeutics Inc

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Appili Therapeutics Inc

Evofem Announces Voting Results from Special Meeting of Stockholders
Evofem's "Say Vagina" Campaign Generates More than 2.5 Million Views Across Social Media Platforms
Evofem Anticipates Approval of Merger with Aditxt at Upcoming Stockholder Meeting
Aditxt's Subsidiary Adimune Highlights Its Approach to Reprogramming the Immune System Through DNA Instructions, Now with 96 Granted and 22 Pending Patents Targeting Autoimmunity Market Estimated at Over $160 Billion by 2030
Illinois Pharmacists Can Prescribe PHEXXI Starting January 2026 Under Newly-passed Law
Aditxt and Crypto.com Sign Agreement for Custodial Crypto Account, Announce ADTX Share Access on Crypto.com as Part of the Larger bitXbio(TM) Initiative
Evofem CEO Saundra Pelletier Honored with Trailblazing Female Founders Award at STIMULATE Conference
Aditxt's Subsidiary, Pearsanta, Inc. Engages Spartan Capital as Lead Underwriter for its Planned IPO Intending to Drive Clinical Validation and Commercial Rollout of Its Mitomic(TM) Platform Technology for Early Detection of Cancers and Other Diseases

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.